The GINAKIT2 trial (NCT03294954) evaluated autologous GD2-CAR-iNKT incorporating CD28/CD3ζ intracellular domains and IL-15 secretion in pediatric patients with relapsed or refractory neuroblastoma. This evidence concerns the gene IL15 and neuroblastoma.